Showing posts with label Corrective and preventive action. Show all posts
Showing posts with label Corrective and preventive action. Show all posts

Tuesday, June 19, 2012

Warning: Your “Check CAPA” Light is On - FDA Form 483

Warning: Your “Check CAPA” Light is On | Ask Cato:

The FDA has reported that over 50% of the top 10 Form FDA 483 observations and warning letters are related to one process: CAPA, otherwise known as Corrective and Preventive Actions.

"The requirements are summarized as follows:

  1. Analyze processes to identify the root cause of the nonconformance and to proactively identify potential causes of future nonconformance;
  2. Investigate the cause;
  3. Identify actions needed to correct and prevent nonconformance recurrence;
  4. Validate that the CAPA is effective and does not cause unintended adverse effects;
  5. Implement and record changes in procedures to correct and prevent the recurrence of noncompliance;
  6. Ensure direct dissemination of CAPA information to those responsible for assuring product quality to ensure adequate training for preventive actions; and
  7. Submit the relevant documentation on CAPA for management review."
'via Blog this'

You might also be interested in:
Root Cause Analysis for Better Investigations - A highly recommended QSR or GMP training course

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - GMP and QSR Compliance Training Experts
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

Tuesday, May 1, 2012

FDA Warning Letters in 2011 Mostly Focused on Batch Failures

Analysis: FDA Warning Letters in 2011 Mostly Focused on Batch Failures - RAPS - News - Article View:

"An analysis of US Food and Drug Administration (FDA) warning letters issued in 2011 shows the majority of all facilities receiving a warning letter were deficient in areas relating to batch failure investigation, reports In-Pharma Technologist.

“In the manufacturing-related warning letters analyzed by in-Pharma Technologist, FDA made 211 numbered observations,” of which 10% were related to the company not investigating batch failures."

'via Blog this'

You might also be interested in:
Faster Product Release Through Efficient Batch Record Review - Onsite Training Class
Root Cause Analysis for Better Investigations - Onsite Training Class

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - GMP and QSR Compliance Training Experts
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

From SkillsPlus International Inc.